(Q)SAR assessments of potentially mutagenic impurities: A regulatory perspective on the utility of expert knowledge and data submission

Current Status of Methods for Defining the Applicability Domain of (Quantitative) Structure-Activity Relationships

Tatiana I. Netzeva, Andrew Worth, Tom Aldenberg et al. · Alternatives to Laboratory Animals · 2005 · 814 citations

Pharmacy, Pharmacology, Drug Design +9

Derivation and Validation of Toxicophores for Mutagenicity Prediction

Jeroen Kazius, Ross McGuire, Roberta Bursi · Journal of Medicinal Chemistry · 2004 · 656 citations

Pharmacy, Toxicology, Mechanisms Of Toxicity +12

Comparison of Different Approaches to Define the Applicability Domain of QSAR Models

Faizan Sahigara, Kamel Mansouri, Davide Ballabio et al. · Molecules · 2012 · 608 citations · Full text

Pharmacy, Medicinal Chemistry, Drug Design +15

A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity

Lutz Müller, Robert J. Mauthe, Christopher M. Riley et al. · Regulatory Toxicology and Pharmacology · 2006 · 461 citations

Pharmacy, Pharmaceutics, Toxicology +12

Classification according to chemical structure, mutagenicity to Salmonella and level of carcinogenicity of a further 39 chemicals tested for carcinogenicity by the U.S. National Toxicology Program

Raymond W. Tennant, John Ashby · Mutation Research/Reviews in Genetic Toxicology · 1991 · 227 citations

Pharmacy, Toxicology, Environmental Toxicology +8